MENU
+Compare
ENZ
Stock ticker: NYSE
AS OF
Feb 21 closing price
Price
$0.52
Change
-$0.01 (-1.89%)
Capitalization
64.03M

ENZ Enzo Biochem Forecast, Technical & Fundamental Analysis

a developer of molecular technology products

ENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ENZ with price predictions
Feb 21, 2025

ENZ's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ENZ turned positive on February 19, 2025. Looking at past instances where ENZ's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENZ's RSI Indicator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where ENZ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ENZ advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

ENZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ENZ entered a downward trend on February 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.905) is normal, around the industry mean (23.448). P/E Ratio (208.333) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.904) is also within normal values, averaging (41.230).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ENZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

View a ticker or compare two or three
ENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of molecular technology products

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
527 Madison Avenue
Phone
+1 212 583-0100
Employees
190
Web
https://www.enzo.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HOWL1.38N/A
N/A
Werewolf Therapeutics
BEP23.44-0.14
-0.59%
Brookfield Renewable Partners LP
BSX104.49-0.87
-0.83%
Boston Scientific Corp
WVE11.13-0.20
-1.77%
Wave Life Sciences Ltd
LFMD5.46-2.06
-27.39%
LifeMD

ENZ and Stocks

Correlation & Price change

A.I.dvisor tells us that ENZ and SINT have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENZ and SINT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENZ
1D Price
Change %
ENZ100%
-2.07%
SINT - ENZ
30%
Poorly correlated
+10.62%
QIPT - ENZ
27%
Poorly correlated
-2.31%
MASS - ENZ
26%
Poorly correlated
-6.99%
SIBN - ENZ
26%
Poorly correlated
-0.89%
TWST - ENZ
26%
Poorly correlated
-8.36%
More